Centro de Estudios Sociosanitarios, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain.
Facultad de Enfermería de Cuenca, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain.
Int J Environ Res Public Health. 2021 Mar 18;18(6):3123. doi: 10.3390/ijerph18063123.
Flash glucose monitoring (FGM) systems have been suggested to have clinical beneficial effects in patients with diabetes mellitus, although their improvements in terms of quality of life (QoL) and patients' satisfaction are not always addressed or are considered a secondary outcome. Thus, the aim of this meta-review is to establish the benefits of FGM in terms of patients' satisfaction and QoL in both type 1 and type 2 diabetes patients using evidence from past systematic reviews and meta-analyses. Major databases were searched for systematic reviews (with or without meta-analyses) that assessed the satisfaction or QoL of type 1 or 2 diabetes patients using FGM compared with other glucose monitoring systems. The quality of the included systematic reviews was addressed with the Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) tool. Six systematic reviews (including two meta-analyses) were included in the meta-review. Evidence suggests that FGM systems seem to improve patients' satisfaction and QoL compared with self-monitoring of blood glucose, although the high variability in the measurement tools, the clinical significance and the quality of the systematic reviews included do not allow us to state FGM benefits with any certainty. Further research, including high-quality randomised clinical trials, differentiating the needs of both type 1 and type 2 diabetes patients and focusing on psychosocial benefits for these patients is needed to optimise clinical decisions between patients and professionals by developing the right health technology assessment for FGM systems.
实时血糖监测（FGM）系统被认为对糖尿病患者具有临床有益效果，尽管它们在生活质量（QoL）和患者满意度方面的改善并未得到充分关注或被视为次要结果。因此，本综述的目的是通过过去的系统评价和荟萃分析，确定 FGM 在 1 型和 2 型糖尿病患者的满意度和 QoL 方面的获益。主要数据库中检索了评估使用 FGM 与其他血糖监测系统相比，1 型或 2 型糖尿病患者满意度或 QoL 的系统评价（无论是否进行荟萃分析）。使用 AMSTAR-2 工具评估纳入系统评价的质量。Meta 综述纳入了 6 项系统评价（包括 2 项荟萃分析）。证据表明，与自我血糖监测相比，FGM 系统似乎可以提高患者的满意度和 QoL，但纳入的系统评价在测量工具的高度变异性、临床意义和质量方面存在差异，这使得我们无法确定 FGM 的获益。需要进一步研究，包括高质量的随机临床试验，区分 1 型和 2 型糖尿病患者的需求，并关注这些患者的心理社会获益，通过为 FGM 系统制定正确的卫生技术评估，优化患者和专业人员之间的临床决策。
